Exjade (deferasirox) is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias.

  • Fatal gastrointestinal (GI) hemorrhages, especially in elderly patients who had advanced hematologic malignancies and/or low platelet counts, have been reported. Nonfatal upper GI irritation, ulceration, and hemorrhage have been reported in patients, including children and adolescents.
  • Patients are advised against using Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants.
  • Exjade may cause renal impairment, including failure; hepatic impairment, including failure; and gastrointestinal hemorrhage.